Thymosin alpha-1 nasal spray needs evidence from the nose.
A spray may sound like a simpler way to use a peptide. But changing the route changes the question. An injection study can’t tell you what a spray delivers or whether it helps.
A listing tells you what’s being offered
Thymosin alpha-1 is a peptide studied for effects on the immune system. Its man-made version is called thymalfasin. It’s a different subject from the copper peptide in a face cream, even if both turn up in a search for peptides.
In its 2024 research review, FDA described thymosin alpha-1 being advertised online as injections and nasal sprays. That was a description of marketing. It wasn’t evidence that a spray worked, and FDA had approved no drug containing the peptide.
An online listing can show the name and format. It can’t replace research on what’s in the bottle, how much reaches its destination or what happens to people using it.
Injection research stays with the injection
The same FDA review found insufficient evidence for the injected uses it examined. It described studies with small groups and weaknesses in their design. That doesn’t mean every possible use has been disproved. It means the evidence didn’t establish effectiveness for those uses.
Nor does it answer the nasal question. Something injected under skin and something sprayed into the nose meet different surfaces. Sharing an ingredient doesn’t fill in the missing steps.
This is why we keep asking about the exact preparation. A paper about a different route can be useful background, but it can’t do the spray’s research for it. Our comparison page follows that distinction across the site.
The safety information has a route, too
FDA’s review raises concerns about ingredient quality, impurities and clumping. In an injection, those problems may cause the body’s immune defences to react. The review also describes soreness, redness and irritation where injections were given.
Those are injection findings and concerns, rather than a safety record for the nose. Switching the format doesn’t show that a quality problem has been solved. A nasal preparation needs its own safety information.
“No needle” can describe a spray perfectly well. It still doesn’t answer “does this help?” or “what are its risks?” Those questions remain about the finished preparation, not just how easy it looks to use.
Withdrawn doesn’t mean cleared
On FDA’s safety-risk page, current as of April 22, 2026, thymosin alpha-1 appears under withdrawn nominations. FDA’s safety concerns remain beside the entry. A withdrawn request isn’t approval or clearance for compounding.
The sources here don’t establish an effective nasal-spray preparation. We leave that gap visible, with the source notes nearby. There’s no spray recipe, schedule or personal treatment advice to extract from an unanswered question.